MedTrace Logo

BAFF and APRIL and RESPONSE TO BELIMUMAB in SLE

NCT03919643 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-04-18

No results posted yet for this study

Summary

This project is intended to identify the routes on which BAFF and APRIL act in order to detect possible future candidates to Belimumab treatment among patients diagnosed of SLE.

Conditions

Sponsors & Collaborators

  • Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2020-05-01
Completion
2020-07-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03919643 on ClinicalTrials.gov